In patients with isolated superficial vein thrombosis, cancer was associated with a higher risk of symptomatic VTE at 3 months compared to non-cancer patients (13.0% vs 5.4%; HR 2.6, 95% CI 1.3-5.0).
Observational (n=1,151)
Does active cancer increase the risk of symptomatic venous thromboembolism in patients with acute isolated superficial vein thrombosis?
Cancer patients with isolated superficial vein thrombosis have a significantly higher risk of symptomatic VTE compared to non-cancer patients, especially within the first 3 months.
Hazard Ratio: 2.6 (95% CI 1.3–5)
Absolute Event Rate: 13% vs 5.4%
BackgroundDespite significant progress in the understanding of paraneoplastic deep vein thrombosis (DVT) and pulmonary embolism (PE), little is known about the outcomes of cancer-associated superficial vein thrombosis (SVT) in daily practice.MethodsINSIGHTS-SVT was a prospective observational study on patients with acute isolated SVT. Primary outcome measure was symptomatic venous thromboembolism (VTE), a composite of DVT, PE, and SVT extension/recurrence, at 3 months. Clinically relevant bleeding was also assessed.ResultsOf 1151 patients included, 6.7 % either had active cancer at baseline or were diagnosed with cancer during 12 months of follow-up. At 3 months, symptomatic VTE had occurred in 13.0 % and 5.4 % of cancer and non-cancer patients, respectively (HR 2.6, 95 % CI 1.3–5.0). Regarding secondary outcomes, cancer patients had increased risks of DVT and PE (HR 3.9, 95 % CI 1.3–11.8) and hospitalization due to VTE (HR 11.0, 95 % CI 2.5–49.0). The rate of clinically relevant bleeding was numerically higher in the cancer cohort (3.9 % vs 1.3 %, HR 3.1, 95 % CI 0.9–10.7). At 12 months, the primary composite outcome had occurred in 15.6 % and 11.9 % of cancer and non-cancer patients, respectively (HR 1.9, 95 % CI 1.0–3.5). After adjusting for additional risk factors, including age, history of DVT/PE and cardiovascular risk factors/diseases, the association of cancer with the primary outcome remained statistically significant.ConclusionCancer patients with isolated SVT are at significant risk of symptomatic VTE. While most events occur within 3 months, the VTE risk remains elevated up to one year of follow-up.ClinicalTrials.gov identifier: NCT02699151.
Länger et al. (Fri,) conducted a observational in Acute isolated superficial vein thrombosis (n=1,151). Active or newly diagnosed cancer vs. No cancer was evaluated on Symptomatic venous thromboembolism (VTE), a composite of DVT, PE, and SVT extension/recurrence, at 3 months (HR 2.6, 95% CI 1.3-5.0). In patients with isolated superficial vein thrombosis, cancer was associated with a higher risk of symptomatic VTE at 3 months compared to non-cancer patients (13.0% vs 5.4%; HR 2.6, 95% CI 1.3-5.0).